OpenLB
Open Library of Bioscience

The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.

Abstract

Keywords

References

1. Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424 [DOI: 10.3322/caac.21492]
2. Alfarouk KO et al (2015) Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 15:71 [PMID: 26180516]
3. Delgir S et al (2021) The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutat Res 787:108366 [DOI: 10.1016/j.mrrev.2021.108366]
4. Swift LP et al (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66(9):4863–4871 [PMID: 16651442]
5. Sikora K et al (1999) Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 10(4):385–390 [PMID: 10370779]
6. Denard B, Lee C, Ye J (2012) Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. Elife 1:e00090 [PMID: 23256041]
7. Cao WQ et al (2019) Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal. Biomed Pharmacother 118:109261 [PMID: 31374355]
8. Li Q et al (2020) Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat Commun 11(1):1456 [PMID: 32193458]
9. Wang H, Huang Y (2020) Combination therapy based on nano codelivery for overcoming cancer drug resistance. Med Drug Discov 6:100024 [DOI: 10.1016/j.medidd.2020.100024]
10. Du F et al (2019) miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis 10(12):922 [PMID: 31801953]
11. Choi YH, Yu AM (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20(5):793–807 [PMID: 23688078]
12. Cox J, Weinman S (2016) Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol 3(1):57–59 [PMID: 26998221]
13. Wang Y et al (2020) Berberine reverses doxorubicin resistance by inhibiting autophagy through the PTEN/Akt/mTOR signaling pathway in breast cancer. Onco Targets Ther 13:1909–1919 [PMID: 32184626]
14. Chen DR et al (2014) Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. Biomed Res Int 204:32161
15. Pfitzer L et al (2019) Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy. Cell Death Dis 10(4):302 [PMID: 30944311]
16. Christowitz C et al (2019) Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer 19(1):757 [PMID: 31370818]
17. Zare M et al (2018) Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol 233(5):3729–3744 [PMID: 28771724]
18. Peng Y, Croce CM (2016) The role of MicroRNAs in human cancer. Signal Transduct Target Ther 1:15004 [PMID: 29263891]
19. Ilkhani K et al (2021) Clinical and in silico outcomes of the expression of miR-130a-5p and miR-615-3p in tumor compared with non-tumor adjacent tissues of patients with BC. Anticancer Agents Med Chem 21(7):927–935 [PMID: 32972352]
20. Magee P, Shi L, Garofalo M (2015) Role of microRNAs in chemoresistance. Ann Transl Med 3(21):332 [PMID: 26734642]
21. Simonson B, Das S (2015) MicroRNA therapeutics: the next magic bullet? Mini Rev Med Chem 15(6):467–474 [PMID: 25807941]
22. Ilkhani K et al (2021) The engaged role of tumor microenvironment in cancer metabolism: focusing on cancer-associated fibroblast and exosome mediators. Anticancer Agents Med Chem 21(2):254–266 [PMID: 32914721]
23. Gorini S et al (2018) Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018:7582730 [PMID: 29743983]
24. Pubchem, Doxorubicin 2021, National Center for Biotechnology Information (2020) PubChem compound summary for CID 31703, doxorubicin. Retrieved 18 Nov 2020 from https://pubchem.ncbi.nlm.nih.gov/compound/Doxorubicin .
25. Edwardson DW et al (2015) Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines. Curr Drug Metab 16(6):412–426 [PMID: 26321196]
26. Kluza J et al (2004) Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23(42):7018–7030 [PMID: 15273722]
27. Butowska K et al (2021) Polymeric nanocarriers: a transformation in doxorubicin therapies. Materials (Basel) 14(9):2135 [DOI: 10.3390/ma14092135]
28. Shivakumar P et al (2012) A study on the toxic effects of Doxorubicin on the histology of certain organs. Toxicol Int 19(3):241–244 [PMID: 23293460]
29. Shankaranarayanan JS et al (2016) doxorubicin conjugated to immunomodulatory anticancer lactoferrin displays improved cytotoxicity overcoming prostate cancer chemo resistance and inhibits tumour development in TRAMP mice. Sci Rep 6:32062 [PMID: 27576789]
30. Sacco G et al (2003) Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 139(3):641–651 [PMID: 12788824]
31. Tayeh Z, Ofir R (2018) Asteriscus graveolens extract in combination with cisplatin/etoposide/doxorubicin suppresses lymphoma cell growth through induction of caspase-3 dependent apoptosis. Int J Mol Sci 19(8):2219 [>PMCID: ]
32. Xu F et al (2017) MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma. Cancer Med 6(3):651–661 [PMID: 28135055]
33. Kopp F et al (2012) miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE 7(11):e50469 [PMID: 23209748]
34. Ma J, Dong C, Ji C (2010) MicroRNA and drug resistance. Cancer Gene Ther 17(8):523–531 [PMID: 20467450]
35. Zhang B et al (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12 [PMID: 16989803]
36. He M et al (2016) MicroRNAs, DNA damage response, and cancer treatment. Int J Mol Sci 17(12):2087 [>PMCID: ]
37. Jin F et al (2017) MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 8(1):2540 [DOI: 10.1038/cddis.2016.461]
38. Talebian S et al (2020) The role of epigenetics and non-coding RNAs in autophagy: A new perspective for thorough understanding. Mech Ageing Dev 190:111309 [PMID: 32634442]
39. Kubiliute R et al (2016) Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line. Med (Kaunas) 52(5):298–306
40. Borges HL, Linden R, Wang JY (2008) DNA damage-induced cell death: lessons from the central nervous system. Cell Res 18(1):17–26 [PMID: 18087290]
41. Yang F, Kemp CJ, Henikoff S (2015) Anthracyclines induce double-strand DNA breaks at active gene promoters. Mutat Res 773:9–15 [PMID: 25705119]
42. Wang Y, Taniguchi T (2013) MicroRNAs and DNA damage response: implications for cancer therapy. Cell Cycle 12(1):32–42 [PMID: 23255103]
43. Davalli P et al (2018) Targeting oxidatively induced DNA damage response in cancer: opportunities for novel cancer therapies. Oxid Med Cell Longev 2018:2389523 [PMID: 29770165]
44. Wu Q, Ketley RF, Gullerova M (2020) Jack of all trades? The versatility of RNA in DNA double-strand break repair. Essays Biochem 64(5):721–735 [DOI: 10.1042/EBC20200008]
45. Zhang X, Lu X (2011) Posttranscriptional regulation of miRNAs in the DNA damage response. RNA Biol 8(6):960–963 [PMID: 21941125]
46. Gajda E et al (2021) The role of miRNA-7 in the biology of cancer and modulation of drug resistance. Pharmaceut (Basel) 14(2):149 [DOI: 10.3390/ph14020149]
47. Lai J et al (2019) MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer. BMC Cancer 19(1):602 [PMID: 31215481]
48. Caron MC et al (2019) Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat Commun 10(1):2954 [PMID: 31273204]
49. Shen Q et al (2014) Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. FEBS Lett 588(1):184–191 [PMID: 24316511]
50. Ismail IH et al (2010) BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191(1):45–60 [PMID: 20921134]
51. Patel N et al (2017) Erratum: miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin. Sci Rep 7(1):12932 [PMID: 29018209]
52. Menon V, Povirk L (2014) Involvement of p53 in the repair of DNA double strand breaks: multifaceted Roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). Subcell Biochem 85:321–336 [PMID: 25201202]
53. Fischer M (2017) Census and evaluation of p53 target genes. Oncogene 36(28):3943–3956 [PMID: 28288132]
54. Tsuchiya N et al (2011) Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 71(13):4628–4639 [PMID: 21565979]
55. Ivanovska I et al (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28(7):2167–2174 [PMID: 18212054]
56. Lin S et al (2019) Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis 10(9):666 [PMID: 31511498]
57. Gao X et al (2019) MicroRNA-16 sensitizes drug-resistant breast cancer cells to Adriamycin by targeting Wip1 and Bcl-2. Oncol Lett 18(3):2897–2906 [PMID: 31452770]
58. Zhang X et al (2010) Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 70(18):7176–7186 [PMID: 20668064]
59. Hall AE et al (2016) The cytoskeleton adaptor protein ankyrin-1 is upregulated by p53 following DNA damage and alters cell migration. Cell Death Dis 7:e2184 [PMID: 27054339]
60. Fornari F et al (2009) MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69(14):5761–5767 [PMID: 19584283]
61. Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140(15):3079–3093 [PMID: 23861057]
62. Johnson N, Shapiro GI (2010) Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 14(11):1199–1212 [PMID: 20932174]
63. Tormo E et al (2019) The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci Rep 9(1):5316 [PMID: 30926829]
64. Xu YY et al (2019) MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression. Kaohsiung J Med Sci 35(5):277–283 [PMID: 30897301]
65. Bohlig L, Friedrich M, Engeland K (2011) p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res 39(2):440–453 [PMID: 20833636]
66. Yuan YL et al (2019) MiR-26a-5p inhibits cell proliferation and enhances doxorubicin sensitivity in HCC cells via targeting AURKA. Technol Cancer Res Treat 18:1533033819851833 [PMID: 31570091]
67. Demel HR et al (2015) Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. Am J Cancer Res 5(5):1649–1664 [PMID: 26175935]
68. De P et al (2014) Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia 16(1):43–72 [PMID: 24563619]
69. Wei F, Yan J, Tang D (2011) Extracellular signal-regulated kinases modulate DNA damage response—a contributing factor to using MEK inhibitors in cancer therapy. Curr Med Chem 18(35):5476–5482 [PMID: 22087839]
70. Hu M et al (2019) MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review). Oncol Rep 41(3):1439–1454 [PMID: 30628706]
71. Hu Y et al (2016) miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis 7(6):e2291 [PMID: 27362808]
72. Zhao Z et al (2014) Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation. Cancer Biol Ther 15(10):1404–1412 [PMID: 25046105]
73. Yu Z et al (2014) miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget 5(4):1083–1090 [PMID: 24658544]
74. Yan ZX et al (2015) MicroRNA181a is overexpressed in T-Cell leukemia/lymphoma and related to chemoresistance. Biomed Res Int 2015:197241 [PMID: 26436088]
75. Zhao L et al (2016) Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget 7(37):60074–60086 [PMID: 27527856]
76. Xiao Q et al (2017) MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2. Oncotarget 8(21):34678–34686 [PMID: 28416774]
77. Astuti I et al (2019) MicroRNA-21 and PTEN expression levels are negatively correlated in doxorubicin resistant MCF-7 breast cancer cell line
78. Tao J et al (2011) microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 25(6):1721–1729 [PMID: 21468550]
79. Liu T, Guo J, Zhang X (2019) MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway. Cancer Biol Ther 20(7):989–998 [PMID: 30983514]
80. Miao Y et al (2017) MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep 7:41942 [PMID: 28165066]
81. Yin Y et al (2020) MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling. Cancer Med 9(4):1544–1552 [PMID: 31899608]
82. Wang DD et al (2016) miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27(kip1) pathway. Tumour Biol 37(11):15315–15324 [PMID: 27699665]
83. Abrams SL et al (2010) The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9(9):1781–1791 [PMID: 20436278]
84. Li L et al (2016) The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett 12(5):3045–3050 [PMID: 27899961]
85. Xiao Y et al (2017) MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Oncol Lett 13(6):4986–4994 [PMID: 28599501]
86. Liu M et al (2020) MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7. J BUON 25(1):472–478 [PMID: 32277671]
87. Zhao L et al (2016) MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 35:25 [PMID: 26842910]
88. Ling Z et al (2020) MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2. Exp Ther Med 19(1):481–488 [PMID: 31897096]
89. Wang YF et al (2019) MicroRNA-608 promotes apoptosis in non-small cell lung cancer cells treated with doxorubicin through the inhibition of TFAP4. Front Genet 10:809 [PMID: 31552102]
90. Bolandghamat Pour Z et al (2019) Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin. BMC Cancer 19(1):1027 [PMID: 31675930]
91. Zhang Y et al (2019) miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A. Kaohsiung J Med Sci 35(1):17–23 [PMID: 30844143]
92. Sun FD et al (2018) MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. Eur Rev Med Pharmacol Sci 22(5):1342–1350 [PMID: 29565492]
93. Chen J et al (2018) miR215p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med 41(4):1855–1866 [PMID: 29393355]
94. L’Ecuyer T et al (2006) DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291(3):H1273–H1280 [PMID: 16565313]
95. Luzhna L et al (2013) Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells. Int J Oncol 42(5):1692–1708 [PMID: 23467667]
96. An X et al (2017) Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B 7(1):38–51 [PMID: 28119807]
97. Mognato M, Celotti L (2015) MicroRNAs used in combination with anti-cancer treatments can enhance therapy efficacy. Mini Rev Med Chem 15(13):1052–1062 [PMID: 26156420]
98. Pearce MC et al (2018) Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. Oncotarget 9(40):26072–26085 [PMID: 29899843]
99. Kale J, Osterlund EJ, Andrews DW (2018) BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25(1):65–80 [PMID: 29149100]
100. Mao F et al (2019) miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma. Cancer Cell Int 19:357 [PMID: 31889909]
101. Verdoodt B et al (2013) MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol 43(1):307–314 [PMID: 23612742]
102. Pan Y et al (2014) Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. Oncol Rep 32(6):2549–2556 [PMID: 25322930]
103. Lin BC et al (2016) MicroRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1. Med Sci Monit 22:1761–1765 [PMID: 27222034]
104. Dong Z et al (2017) Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. Br J Cancer 116(12):1572–1584 [PMID: 28494471]
105. Long J et al (2015) miR-193b modulates resistance to doxorubicin in human breast cancer cells by downregulating MCL-1. Biomed Res Int 2015:373574 [PMID: 26526790]
106. Osaki S et al (2016) Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. Sci Rep 6:28953 [PMID: 27356624]
107. Kim EA et al (2016) Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget 7(22):31832–31846 [PMID: 27092874]
108. Shu Y et al (2017) MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway. Oncotarget 8(57):97313–97322 [PMID: 29228612]
109. Zheng Y et al (2016) MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep 35(2):683–690 [PMID: 26572075]
110. Dai H et al. (2019) MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. Biosci Rep 39(7)
111. Sun Y et al (2016) MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma. Sci Rep 6:34238 [PMID: 27681638]
112. Xu YC et al (2018) A novel mechanism of doxorubicin resistance and tumorigenesis mediated by MicroRNA-501-5p-suppressed BLID. Mol Ther Nucleic Acids 12:578–590 [PMID: 30195794]
113. Iwai N et al (2018) Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol 53(1):237–245 [PMID: 29658604]
114. Reza A et al (2017) MicroRNA-7641 is a regulator of ribosomal proteins and a promising targeting factor to improve the efficacy of cancer therapy. Sci Rep 7(1):8365 [PMID: 28827731]
115. Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27(16):2312–2319 [PMID: 18391973]
116. Han CY et al (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29(9):1837–1844 [PMID: 18390843]
117. Soheilifar MH et al. (2020) Concomitant overexpression of mir-182–5p and mir-182–3p raises the possibility of IL-17-producing Treg formation in breast cancer by targeting CD3d, ITK, FOXO1, and NFATs: a meta-analysis and experimental study. Cancer Sci
118. Lang C et al (2018) MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1. Oncol Lett 16(3):4020–4026 [PMID: 30128023]
119. Wang H et al (2019) Downregulation of miR-222-3p reverses doxorubicin-resistance in LoVo cells through upregulating forkhead box protein P2 (FOXP2) protein. Med Sci Monit 25:2169–2178 [PMID: 30904920]
120. Pang X et al (2019) Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol 16(2):233–248 [PMID: 30628514]
121. Seo HA et al (2019) MicroRNA-based combinatorial cancer therapy: effects of MicroRNAs on the efficacy of anti-cancer therapies. Cells 9(1):29 [>PMCID: ]
122. Zhou Y et al (2019) miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 10(11):843 [PMID: 31695022]
123. Chavez-Dominguez R et al (2020) The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity. Front Oncol 10:578418 [PMID: 33117715]
124. Denton D, Kumar S (2019) Autophagy-dependent cell death. Cell Death Differ 26(4):605–616 [PMID: 30568239]
125. Soni M et al (2018) Autophagy, cell viability, and chemoresistance are regulated by miR-489 in breast cancer. Mol Cancer Res 16(9):1348–1360 [PMID: 29784669]
126. Zhu K et al (2020) LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22. Aging (Albany NY) 12(8):6644–6666 [DOI: 10.18632/aging.103004]
127. Chen R et al (2017) MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep 15(3):1326–1334 [PMID: 28138700]
128. Xu R et al (2016) MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy. Oncol Rep 35(3):1757–1763 [PMID: 26708607]
129. Cui X et al (2020) MicroRNA200a enhances antitumor effects in combination with doxorubicin in hepatocellular carcinoma. Transl Oncol 13(10):100805 [PMID: 32563177]
130. Wei R et al (2016) miR-140–5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells. Biosci Rep 36(5)
131. Chang Z et al (2014) Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. Sci World J 14:794756
132. Meng Y et al (2017) MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. Sci Rep 7(1):416 [PMID: 28341864]
133. Liang L et al (2020) MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B 10(6):1036–1046 [PMID: 32642410]
134. Muriithi W et al (2020) ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med 17(2):253–269 [PMID: 32587767]
135. Ariana M et al (2018) The diversity in the expression profile of caveolin II transcripts, considering its new transcript in breast cancer. J Cell Biochem 119(2):2168–2178 [PMID: 28857238]
136. Lee CY et al (2016) The influence of a caveolin-1 mutant on the function of P-glycoprotein. Sci Rep 6:20486 [PMID: 26843476]
137. Zou Z et al (2017) miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med 21(9):1929–1943 [PMID: 28411377]
138. Takwi AA et al (2014) miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene 33(28):3717–3729 [PMID: 23934188]
139. Shang Y et al (2014) miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 33(25):3267–3276 [PMID: 23893241]
140. Xu Y et al (2013) Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS ONE 8(11):82062 [DOI: 10.1371/journal.pone.0082062]
141. Chen J et al (2012) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29(4):2527–2534 [PMID: 22101791]
142. Chen Z et al (2020) The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the wnt/beta-catenin signaling pathway. Mol Ther Nucleic Acids 19:1434–1448 [PMID: 32160712]
143. Bao L et al (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180(6):2490–2503 [PMID: 22521303]
144. Liang Z et al (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79(6):817–824 [PMID: 19883630]
145. Gao M et al (2016) miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget 7(37):59714–59726 [PMID: 27487127]
146. Lu L et al (2015) MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnol Lett 37(12):2387–2394 [PMID: 26318721]
147. Pan YZ et al (2013) Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 41(10):1744–1751 [PMID: 23686318]
148. Hou H et al (2017) miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1. Neoplasma 64(1):81–91 [PMID: 27881008]
149. Zheng D et al (2015) MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1. Int J Clin Exp Pathol 8(9):10072–10081 [PMID: 26617714]
150. Chen X, Wang YW, Gao P (2018) SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer. J Exp Clin Cancer Res 37(1):100 [PMID: 29743122]
151. Khan AQ et al. (2019) Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells 8(8)
152. Mohammed MK et al (2016) Wnt/beta-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis 3(1):11–40 [PMID: 27077077]
153. Guo Y et al (2018) Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/beta-catenin pathway. Cancer Manag Res 10:4371–4380 [PMID: 30349370]
154. Zheng Z et al (2016) MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/beta-catenin signaling pathway. Oncotarget 7(19):28000–28012 [PMID: 27058905]
155. Kim do Y et al (2016) A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/beta-catenin signaling in breast cancer. Oncotarget 7(12):14791–14802 [PMID: 26895471]
156. Park EY et al (2014) Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 74(24):7573–7582 [PMID: 25368020]
157. Xu M et al (2015) miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther 23(1):89–98 [PMID: 25292190]
158. Gao L et al (2019) MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. EBioMedicine 41:395–407 [PMID: 30803931]
159. Wang SS et al (2015) Links between cancer stem cells and epithelial-mesenchymal transition. Onco Targets Ther 8:2973–2980 [PMID: 26527883]
160. Dudas J et al (2020) Epithelial to mesenchymal transition: a mechanism that fuels cancer radio/chemoresistance. Cells 9(2)
161. Long L et al (2019) ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells. Exp Mol Pathol 106:116–122 [PMID: 30615851]
162. Kwok GTY et al (2019) microRNA-431 as a chemosensitizer and potentiator of drug activity in adrenocortical carcinoma. Oncologist 24(6):e241–e250 [PMID: 30918109]
163. Lee JW et al (2018) MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Sci 109(5):1404–1413 [PMID: 29575368]
164. Jin Z et al (2016) MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. Eur Rev Med Pharmacol Sci 20(6):1080–1086 [PMID: 27049260]
165. Hu SH et al (2016) miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells. Eur Rev Med Pharmacol Sci 20(23):5002–5008 [PMID: 27981531]
166. Zhou Y et al (2014) The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death Differ 21(3):462–474 [PMID: 24270410]
167. Chu S et al (2017) miR-93 and PTEN: key regulators of doxorubicin-resistance and EMT in breast cancer. Oncol Rep 38(4):2401–2407 [PMID: 28765915]
168. Tryndyak VP, Beland FA, Pogribny IP (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126(11):2575–2583 [PMID: 19839049]
169. Chen Y et al (2013) miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep 7(5):1579–1584 [PMID: 23546450]
170. Alam F et al (2017) The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells. Tumour Biol 39(9):1010428317714634 [PMID: 28933253]
171. Bockhorn J et al (2013) MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393 [PMID: 23340433]
172. Guan X et al (2019) MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition. Oncol Lett 18(6):5986–5994 [PMID: 31788073]
173. Tu C et al (2019) MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2. J Cell Mol Med 23(11):7190–7199 [PMID: 30801960]
174. Li Y et al (2018) MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 9(1):14 [PMID: 29323124]
175. Tao L et al (2020) MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc. Biomed Pharmacother 125:109962 [PMID: 32106373]
176. Wang J et al (2017) Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 8(48):84559–84571 [PMID: 29137448]
177. Zhang Y, Wang Z, Gemeinhart RA (2013) Progress in microRNA delivery. J Control Release 172(3):962–974 [PMID: 24075926]
178. Salzano G et al (2016) Mixed nanosized polymeric micelles as promoter of doxorubicin and miRNA-34a co-delivery triggered by dual stimuli in tumor tissue. Small 12(35):4837–4848 [PMID: 27432595]
179. Zhao Y et al (2015) Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. Biochem Pharmacol 98(4):602–613 [PMID: 26518752]
180. Lou G et al (2020) MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J Exp Clin Cancer Res 39(1):4 [PMID: 31898515]
181. Gajda E et al (2020) Combinatory treatment with miR-7–5p and drug-loaded cubosomes effectively impairs cancer cells. Int J Mol Sci 21(14)
182. Chen W et al (2019) Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Biomaterials 192:590–600 [PMID: 30553134]
183. Xue H et al (2017) Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. Int J Nanomed 12:5271–5287 [DOI: 10.2147/IJN.S135306]
184. Fan YP et al (2017) MiR-375 and doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma. Mol Ther Nucleic Acids 7:181–189 [PMID: 28624193]
185. Gong C et al (2019) Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J Nanobiotechnol 17(1):93 [DOI: 10.1186/s12951-019-0526-7]
186. Yoo B et al (2015) Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Res 75(20):4407–4415 [PMID: 26359455]
187. Rui M et al (2017) Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells. Int J Nanomed 12:217–237 [DOI: 10.2147/IJN.S122171]
188. Safi A et al (2021) miRNAs modulate the dichotomy of cisplatin resistance or sensitivity in breast cancer: an update of therapeutic implications. Anticancer Agents Med Chem 21(9):1069–1081 [PMID: 32885760]

Grants

1. 64694/Tabriz University of Medical Sciences

MeSH Term

Chemicals